The US Food and Drug Administration has approved Gleevec (imatinib mesylate) for a new indication?keeping cancer from growing in patients following surgical removal of a gastrointestinal stromal tumor (GIST).
The US Food and Drug Administration has approved Gleevec (imatinib mesylate) for a new indication—keeping cancer from growing in patients following surgical removal of a gastrointestinal stromal tumor (GIST).
Gleevec, manufactured by Novartis AG (Basel, Switzerland), was first approved by the FDA in 2001 and is one of the first drugs in a class of agents that block cellular communications that result in tumor growth. It is intended to be given to patients following surgery to help prevent tumor recurrence.
GIST is a fairly rare form of cancer that originates in cells found in the wall of the GI tract. Because symptoms of GIST are no different than other GI complaints such as nausea and vomiting, the cancer is difficult to detect early. Patients initially undergo surgery to remove the tumor but GIST commonly recurs.
The efficacy of Gleevec was established in a clinical trial in which patients received either Gleevec or a placebo for one year after surgical removal of the tumor. The optimal treatment duration is not known.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.